AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • October 6th, 2022 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (“Agreement”) is made by and between Orchard Therapeutics plc (the “Parent”), Orchard Therapeutics North America (the “U.S. Subsidiary”), and Frank Thomas (the “Executive”), and is effective as of October 4, 2022 (the “Effective Date”). The Parent, the U.S. Subsidiary, and their respective subsidiaries and other affiliates are collectively referred to herein as the “Company,” and the duties of the Company set forth in this Agreement may be discharged by any entity within that definition.
ORCHARD THERAPEUTICS PLC AMERICAN DEPOSITARY SHARES EACH REPRESENTING ONE ORDINARY SHARE (NOMINAL VALUE £0.10 PER SHARE) SALES AGREEMENTSales Agreement • October 6th, 2022 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • New York
Orchard Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the “Company”), confirms its agreement (this “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”), as follows:
